Your Location:Home > About us

CHINA MIGO INDUSTRIAL CO., LIMITED

Since its establishment in 2008, CHINA MIGO INDUSTRIAL CO., LIMITED has been committed to providing high-standard and high-quality active pharmaceutical ingredients (APIs) to global pharmaceutical companies. From humble beginnings to steady progress, we have weathered challenges while maintaining our reverence for quality and pursuit of innovation. Our core business focuses on the research, development, production, and sales of chemical APIs, intermediates, and pharmaceutical preparations. The company has established an international-standard and continuously improving quality management system, adhering to the quality policy of "Quality First, Customer Supreme, Striving for Excellence, Pursuing Perfection". We implement full life cycle management throughout the entire process from drug research, production, distribution to usage, ensuring the safety, stability, and efficacy of our products. Since 2008, our company has successively passed international certifications from China's NMPA, the US FDA, and the EU EDQM. With the endorsement of these international authoritative certifications, our products have entered global markets and are exported to more than 50 countries and regions, contributing Chinese strength to the practice of building a global community of health for all.

We have a history of over 15 years

2008

Establishment of CHINA MIGO INDUSTRIAL CO., LIMITED, initially focusing on R&D and production of API (Active Pharmaceutical Ingredients).

2009

Formation of core management team and commissioning of the first production facility.

2010

Obtained National Drug Production License.

2011

Successful development and commercial launch of the first core product.

2012

Expansion of production lines and construction of GMP-compliant facilities.

2013

Obtained international official certifications from NMPA, FDA, and EDQM.

2014

Product line expanded to include anti-diabetic, anti-cancer, cardiovascular, and antibiotic drugs.

2015

Established advanced formulation R&D team and introduced sophisticated analysis and testing equipment.

2016

Establishment of provincial-level technology research center.

2017

API products passed international GMP certification.

2018

Successfully entered high-end international markets in North America, Europe, and Japan.

2019

Obtained ISO14001 Environmental Management System certification, implementing green production practices.

2020

Commissioning of smart factory project to build a globally leading API production base with intelligent and green technologies.

2021

Achieved technological breakthroughs in High Potency Active Pharmaceutical Ingredients (HPAPI) and other fields.

2022

Awarded "Five-star Enterprise," "AAA Credit Rating in Pharmaceutical Industry," and "Local Tax Contribution Award."

2023

Total workforce exceeds 300, with R&D personnel accounting for 30%.